Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

Leukemia & lymphoma·2026
Same author

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

British journal of haematology·2026
Same author

Valganciclovir for CMV Prophylaxis After PTCy-Based Allogeneic Hematopoietic Cell Transplantation.

Transplantation and cellular therapy·2026

Related Experiment Video

Updated: Dec 25, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K

Targeting MCL-1 in hematologic malignancies: Rationale and progress.

Andrew H Wei1, Andrew W Roberts2, Andrew Spencer3

  • 1Alfred Hospital and Monash University, Melbourne, VIC, Australia.

Blood Reviews
|March 25, 2020
PubMed
Summary

MCL-1 inhibitors show promise for treating blood cancers like multiple myeloma and leukemia. Clinical trials are evaluating their effectiveness and safety, potentially improving patient outcomes.

Keywords:
Acute myeloid leukemiaBH3-mimeticMCL-1 inhibitorMultiple myelomaNon-Hodgkin lymphoma

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

686
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

686
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein crucial for cancer cell survival.
  • Overexpression of MCL-1 correlates with treatment resistance and poor prognosis in hematologic malignancies.
  • MCL-1 is a validated therapeutic target in multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL).

Purpose of the Study:

  • To review the therapeutic potential of MCL-1 inhibitors in hematologic malignancies.
  • To discuss the clinical development of novel MCL-1 inhibitors.
  • To explore the combination strategies of MCL-1 inhibitors with other anti-cancer agents and assess their safety profile.

Main Methods:

  • Review of preclinical and clinical data on MCL-1 inhibitors.
  • Analysis of the role of MCL-1 in cancer cell survival and treatment resistance.
  • Evaluation of combination therapies involving MCL-1 inhibitors.

Main Results:

  • Several MCL-1 inhibitors (e.g., AZD5991, S64315, AMG 176, AMG 397) are in clinical trials.
  • MCL-1 inhibition demonstrates anti-tumor activity in relevant hematologic malignancies.
  • Investigating synergistic effects with BCL-2 inhibitors and other anti-cancer drugs is ongoing.

Conclusions:

  • MCL-1 inhibitors represent a promising therapeutic strategy for hematologic malignancies.
  • Further clinical evaluation is necessary to establish the safety and efficacy of MCL-1 inhibitors, including combination therapies.
  • Identifying a safe therapeutic window is critical for the successful clinical application of MCL-1 inhibitors.